Temporal Insights into Molecular and Cellular Responses during rAAV Production in HEK293T Cells
Preprint
Abstract
The gene therapy field is actively pursuing cost-effective, large-scale production of recombinant adeno-associated virus (rAAV) vectors for therapeutic applications, which demand high dosages. Enhanced yield is essential but presents technical and cost challenges. Strategies like suspension cell culture, transfection optimization, and cultivation conditions have shown moderate success but fall short for large-scale applications. In this study, we explore the host cell proteome of HEK293T cell lines used for AAV2 production under different transfection conditions (standard, sub-optimal, optimal) using SWATH-MS. To understand molecular and cellular mechanisms, we created a tailored spectral library for HEK293T-AAV interactions. Our gene ontology and pathway analysis revealed significant protein expression variations, particularly in processes related to cellular homeostasis, metabolic regulation, vesicular transport, ribosomal biogenesis, and cellular proliferation under optimal transfection conditions. These conditions increased rAAV titre by 50% compared to standard protocols. Furthermore, we identified alterations in host cell proteins crucial for AAV mRNA stability and gene translation, particularly regarding AAV capsid transcripts in optimal transfection conditions. This study provides insights into cellular mechanisms during rAAV production in HEK293T cells and offers potential advancements in scalability and cost-efficiency for gene therapy vector production. Significance: Generating AAV is challenging and the amount produced is limited, despite the success of gene therapy. Thus, it is necessary to enhance the productivity of host cells through various engineering techniques. The replication and transduction of viruses cause numerous modifications to the host cell’s proteome. Viruses exploit the processes of the host cell, influencing the availability, post-translational adjustments, associations, or placement of its proteins during the replication/growth cycle. Comprehending the fluctuations in biological processes during AAV replication is essential to grasping how virus-host relations shape the result of infection and viral protein expression.Keywords
All Related Versions
- Published version: Molecular Therapy - Methods & Clinical Development, 32 (3), 101278.
This publication has 60 references indexed in Scilit:
- Recent advances in upstream process development for production of recombinant adeno‐associated virusBiotechnology and Bioengineering, 2023
- Transcriptomic features reveal molecular signatures associated with recombinant adeno‐associated virus production in HEK293 cellsBiotechnology Progress, 2023
- Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturingBiotechnology and Bioengineering, 2023
- Advancements in molecular design and bioprocessing of recombinant adeno‐associated virus gene delivery vectors using the insect‐cell baculovirus expression platformBiotechnology Journal, 2020
- Proteome profiling and vector yield optimization in a recombinant adeno‐associated virus‐producing yeast modelMicrobiologyopen, 2020
- Adeno‐associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent themReviews in Medical Virology, 2013
- Intracellular localization of adeno‐associated viral proteins expressed in insect cellsBiotechnology Progress, 2011
- Recent developments in adeno‐associated virus vector technologyThe Journal of Gene Medicine, 2008
- Virus-like Particle and Viral Vector Production Using the Baculovirus Expression Vector System/Insect Cell System2007
- Nuclear Import and Export of Viruses and Virus GenomesVirology, 1998